Cell line · CVCL_0237
Capan-1
Cancer cell line, Homo sapiens. Pancreatic ductal adenocarcinoma. 108 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. Capan-1. Cell lines, record CVCL_0237. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_0237
On this page
Cell line
As Cellosaurus gives it.
- Name
- Capan-1
- Accession
- CVCL_0237
- RRID
- RRID:CVCL_0237
- Synonyms
- CaPan-1, CAPAN-1, Capan 1, CAPAN 1, Capan1, CAPAN1
- Species
- Homo sapiens (Human)
- Sex
- Male
- Age at sampling
- 40Y
- Category
- Cancer cell line
- Diseases
- Pancreatic ductal adenocarcinoma (NCIt C9120)
- Derived from
- Liver (metastatic)
- Entry created
- 2012-04-04
- Entry updated
- 2025-04-10
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers108
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Pharmacokinetic Tuning Redirects β‐Lapachone From NQO1 Bioactivation to Vimentin‐Targeted Oxidation in Cancer | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting SERPINB5 and MSLN for Pancreatic Cancer Therapy. | Cancers (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Bridging the gap: a genetically validated avian chorioallantoic membrane platform for investigation of spontaneous circulating tumor cells. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Activation of PP2A-B56a leads to aberrant EGFR signaling and proliferative phenotypes in PDAC. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Early induction of the Rho-GEF ECT2 drives MEK/ERK oncogenic signaling in pancreatic ductal adenocarcinoma. | Oncogene | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Expression of HER2 in the eye and the potential for on-target side effects with antibody-drug conjugates. | Sci Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting HAS2 to enhance anti-tumor immunity in pancreatic cancer via PD-L1 regulation. | Commun Biol | 2026 | Its Methods give the RRID and name the line | PubMed | |
A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Basroparib inhibits YAP-driven cancers by stabilizing angiomotin. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| GlycoChat Uncovers Glycan-Lectin Circuits in the Tumor Microenvironment of Pancreatic Cancer. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 108
See all 108 papersRelatives2
| Relation | Cell line | Accession | Problem | Source |
|---|---|---|---|---|
| Derived from it | Capan-1 SimpleCell O-GalNAc | CVCL_S022 | Cell lines | |
| Derived from it | Capan1M9 | CVCL_0A59 | Cell lines |
Cell banks8
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| ATCC | HTB-79 | ATCC | |
| AddexBio | C0018001/31 | Cellosaurus | |
| BCRJ | 0265 | BCRJ | |
| CLS | 300143 | CLS | |
| CancerTools | 161907 | CancerTools | |
| DSMZ | ACC-244 | DSMZ | |
| IZSLER | BS TCL 9 | Cellosaurus | |
| KCLB | 30079 | KCLB |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0237
GET https://conductscience.org/api/cell-lines/v1/CVCL_0237/papers?page=2